Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2][2] Since subcutaneous (SC) administration
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2016
|
| In: |
Haematologica
Year: 2016, Jahrgang: 101, Heft: 12, Pages: e485-e487 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2016.151266 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2016.151266 Verlag, Volltext: http://www.haematologica.org/content/101/12/e485 
|
| Verfasserangaben: | Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 156381756X | ||
| 003 | DE-627 | ||
| 005 | 20220813231242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170926s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2016.151266 |2 doi | |
| 035 | |a (DE-627)156381756X | ||
| 035 | |a (DE-576)493817565 | ||
| 035 | |a (DE-599)BSZ493817565 | ||
| 035 | |a (OCoLC)1340979820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Merz, Maximilian |d 1985- |e VerfasserIn |0 (DE-588)1023626950 |0 (DE-627)718419278 |0 (DE-576)367168251 |4 aut | |
| 245 | 1 | 0 | |a Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial |c Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt |
| 264 | 1 | |c December 2016 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.09.2017 | ||
| 520 | |a Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2][2] Since subcutaneous (SC) administration | ||
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Seckinger, Anja |d 1980- |e VerfasserIn |0 (DE-588)134177371 |0 (DE-627)562118225 |0 (DE-576)278603734 |4 aut | |
| 700 | 1 | |a Jauch, Anna |d 1959- |e VerfasserIn |0 (DE-588)1025525140 |0 (DE-627)722525362 |0 (DE-576)168357496 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Schurich, Bärbel |e VerfasserIn |0 (DE-588)1070073237 |0 (DE-627)823264750 |0 (DE-576)429746121 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 101(2016), 12, Seite e485-e487 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial |
| 773 | 1 | 8 | |g volume:101 |g year:2016 |g number:12 |g pages:e485-e487 |g extent:3 |a Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2016.151266 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.haematologica.org/content/101/12/e485 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170926 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 23 |y j | ||
| 998 | |g 1070073237 |a Schurich, Bärbel |m 1070073237:Schurich, Bärbel |d 910000 |d 910100 |e 910000PS1070073237 |e 910100PS1070073237 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1025525140 |a Jauch, Anna |m 1025525140:Jauch, Anna |d 910000 |d 911500 |e 910000PJ1025525140 |e 911500PJ1025525140 |k 0/910000/ |k 1/910000/911500/ |p 12 | ||
| 998 | |g 134177371 |a Seckinger, Anja |m 134177371:Seckinger, Anja |d 910000 |d 910100 |e 910000PS134177371 |e 910100PS134177371 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 910000 |d 910100 |d 50000 |e 910000PH139824995 |e 910100PH139824995 |e 50000PH139824995 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |e 910000PM1049182545 |e 910100PM1049182545 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1023626950 |a Merz, Maximilian |m 1023626950:Merz, Maximilian |d 910000 |d 910100 |e 910000PM1023626950 |e 910100PM1023626950 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN156381756X |e 2981672282 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"part":{"text":"101(2016), 12, Seite e485-e487","issue":"12","pages":"e485-e487","year":"2016","extent":"3","volume":"101"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"origin":[{"dateIssuedKey":"2014","publisher":"Ferrata Storti Foundation","dateIssuedDisp":"2014-","publisherPlace":"Pavia"}],"note":["Gesehen am 27.05.2022"],"pubHistory":["99.2014 -"],"title":[{"subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation","title_sort":"Haematologica","title":"Haematologica"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialHaematologica","recId":"814204899","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2805244-4"],"issn":["1592-8721"],"eki":["814204899"]}}],"recId":"156381756X","physDesc":[{"extent":"3 S."}],"name":{"displayForm":["Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt"]},"id":{"eki":["156381756X"],"doi":["10.3324/haematol.2016.151266"]},"title":[{"title_sort":"Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial","title":"Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial"}],"origin":[{"dateIssuedDisp":"December 2016","dateIssuedKey":"2016"}],"note":["Gesehen am 26.09.2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"display":"Merz, Maximilian","family":"Merz","role":"aut","given":"Maximilian"},{"display":"Mai, Elias K.","family":"Mai","given":"Elias K.","role":"aut"},{"role":"aut","given":"Uta","family":"Bertsch","display":"Bertsch, Uta"},{"given":"Dirk","role":"aut","display":"Hose, Dirk","family":"Hose"},{"given":"Anja","role":"aut","family":"Seckinger","display":"Seckinger, Anja"},{"family":"Jauch","display":"Jauch, Anna","given":"Anna","role":"aut"},{"given":"Jens","role":"aut","family":"Hillengaß","display":"Hillengaß, Jens"},{"family":"Raab","display":"Raab, Marc-Steffen","role":"aut","given":"Marc-Steffen"},{"display":"Schurich, Bärbel","family":"Schurich","role":"aut","given":"Bärbel"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut"}]} | ||
| SRT | |a MERZMAXIMIPERIPHERAL2016 | ||